Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Gold Fields Limited (GFI) Price & Performance

Bristol-Myers Squibb CoTrade
Gold Fields LimitedTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Gold Fields Limited — how do they compare? Bristol-Myers Squibb Co trades at $63.93 (market cap $129.94B), while Gold Fields Limited trades at $41.07 (market cap $36.07B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.6× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (5.76%). Which is the better fit depends on your goals.

BMYGFI
Market Cap
$129.94B$36.07B
Sector
HealthBasic Materials
52-Week High
$65.89$61.52
52-Week Low
$42.60$29.31
Enterprise Value
$163.92B$37.51B
Dividend Yield
3.96%5.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Gold Fields Limited

Gold Fields (GFI) trades at $41.06, down 0.16% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong fundamentals with a P/E of 10.22, net income margin of 40.76%, and robust cash flow growth, with 2025 projections indicating revenue of $8.8B and net income of $3.6B. Recent news highlights institutional buying interest, such as Assenagon Asset Management's new position in Q2 2026.

The outlook for GFI is positive, supported by high profitability and growth projections, though risks include volatile gold prices and cost pressures. Analyst consensus is a Buy with a $52 price target, suggesting 27% upside. Investors should weigh strong cash generation against debt increases and market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Gold Fields Limited

Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.

Read more on GFI